生育力保存进展:2015年巴塞罗那国际生育力保存学会-欧洲人类生殖与胚胎学会-美国生殖医学学会专家会议关于适应证、结果与未来展望的更新
2015年6月在西班牙巴塞罗那召开国际专家会议,20名来自美国生殖医学学会、欧洲人类生殖与胚胎学会和国际生育力保存学会的专家回顾截至2015年6月的文献,更新生育力保存的适应证、结果与未来展望。会议强烈推荐建立国际登记系统以追踪生育力保存技术的短期和长期结局,并指出因缺乏大样本或随机设计研究,多数证据级别为3或以下。
要点
- 胚胎和卵细胞冷冻保存是青春期后女性的一线生育力保存方法,其中MII期卵细胞玻璃化冷冻是首选。
- 精液冷冻保存是男性唯一已确立的生育力保存方法。
- 青春期前男孩应推荐睾丸组织冷冻保存,但自体移植恢复生育力策略尚未在人类中验证安全临床应用。
核心结论
- 生育力保存技术在过去十年已被广泛采用,因此强烈推荐建立关于其短期和长期结局的国际登记系统。
研究设计与样本
- 2015年6月在西班牙巴塞罗那召开的国际会议,由美国生殖医学学会、欧洲人类生殖与胚胎学会和国际生育力保存学会的20名国际生育力保存专家回顾截至2015年6月的文献,讨论并批准最终稿件。
主要发现
- 多种肿瘤和非肿瘤疾病本身或其性腺毒性治疗可能影响当前或未来生育力,需要适当的生育力保存方案。
- 希望推迟生育的女性以及开始激素治疗或切除/改变生殖器官手术前的跨性别个体也应接受相应咨询。
- 胚胎和卵细胞冷冻保存是青春期后女性的一线生育力保存方法,MII期卵细胞玻璃化冷冻是首选。
- 冷冻卵巢组织原位移植后卵巢功能恢复及辅助生殖技术后自然妊娠的累积证据支持其未来作为开放临床应用。
- 精液冷冻保存是男性唯一已确立的生育力保存方法;青春期前男孩应推荐睾丸组织冷冻保存,但自体移植恢复生育力策略尚未在人类中验证安全临床应用。
关键数值与推荐
- 强烈推荐建立关于生育力保存技术短期和长期结局的国际登记系统。
- 胚胎和卵细胞冷冻保存是青春期后女性的一线生育力保存方法。
- MII期卵细胞玻璃化冷冻是青春期后女性生育力保存的首选选项。
- 精液冷冻保存是男性唯一已确立的生育力保存方法。
- 青春期前男孩应推荐睾丸组织冷冻保存。
临床怎么用
- 所有希望保存生育力的个体均应接受关于当前可用生育力保存选项的咨询。
- 青春期后女性可考虑胚胎或卵细胞冷冻保存,MII期卵细胞玻璃化冷冻为首选。
- 男性可考虑精液冷冻保存。
- 青春期前男孩应推荐睾丸组织冷冻保存,但自体移植恢复生育力策略尚未在人类中验证安全临床应用。
局限性
- 因缺乏大样本或随机设计研究,多数回顾证据的证据级别为3或以下。
- 需要进一步高质量研究来研究生育力保存技术的长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What progress has been made in fertility preservation (FP) over the last decade? SUMMARY ANSWER: FP techniques have been widely adopted over the last decade and therefore the establishment of international registries on their short- and long-term outcomes is strongly recommended. WHAT IS KNOWN ALREADY: FP is a fundamental issue for both males and females whose future fertility may be compromised. Reproductive capacity may be seriously affected by age, different medical conditions and also by treatments, especially those with gonadal toxicity. There is general consensus on the need to provide counselling about currently available FP options to all individuals wishing to preserve their fertility. STUDY DESIGN, SIZE, DURATION: An international meeting with representatives from expert scientific societies involved in FP was held in Barcelona, Spain, in June 2015. PARTICIPANTS/MATERIALS, SETTING, METHODS: Twenty international FP experts belonging to the American Society of Reproductive Medicine, ESHRE and the International Society of Fertility Preservation reviewed the literature up to June 2015 to be discussed at the meeting, and approved the final manuscript. At the time this manuscript was being written, new evidence considered relevant for the debated topics was published, and was consequently included. MAIN RESULTS AND THE ROLE OF CHANCE: Several oncological and non-oncological diseases may affect current or future fertility, either caused by the disease itself or the gonadotoxic treatment, and need an adequate FP approach. Women wishing to postpone maternity and transgender individuals before starting hormone therapy or undergoing surgery to remove/alter their reproductive organs should also be counselled accordingly. Embryo and oocyte cryopreservation are first-line FP methods in postpubertal women. Metaphase II oocyte cryopreservation (vitrification) is the preferred option. Cumulative evidence of restoration of ovarian function and spontaneous pregnancies after ART following orthotopic transplantation of cryopreserved ovarian tissue supports its future consideration as an open clinical application. Semen cryopreservation is the only established method for FP in men. Testicular tissue cryopreservation should be recommended in pre-pubertal boys even though fertility restoration strategies by autotransplantation of cryopreserved testicular tissue have not yet been tested for safe clinical use in humans. The establishment of international registries on the short- and long-term outcomes of FP techniques is strongly recommended. LIMITATIONS, REASONS FOR CAUTION: Given the lack of studies in large cohorts or with a randomized design, the level of evidence for most of the evidence reviewed was 3 or below. WIDER IMPLICATIONS OF THE FINDINGS: Further high quality studies are needed to study the long-term outcomes of FP techniques. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.
引用
- Martinez F. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Fertil Steril. 2017. PMID: 28739117. doi:10.1016/j.fertnstert.2017.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。